Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.
Ocular yeast infections in diabetics are a therapeutic challenge. Drug resistance and reduced azole susceptibility are major concerns. The case we describe characterizes a Candida albicans strain from a vitrectomy specimen that was susceptible to fluconazole by in vitro testing but recalcitrant to therapy. Molecular studies revealed transient overexpression of CDR1 and ERG11 mRNA in the presence of fluconazole that may have contributed to poor clinical response in this patient.
Pancholi
Preeti
P
Clinical Microbiology Laboratory, Department of Pathology, New York Presbyterian Hospital, Columbia University Medical Center, 622 West 168th St., CHS 3-326, New York, NY 10032, USA. prp9005@nyp.org
Park
Steven
S
Perlin
David
D
Kubin
Christine
C
Della-Latta
Phyllis
P
D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002176:Candida albicans / Q000187:drug effects* / Q000235:genetics; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology; D025141:Drug Resistance, Fungal / Q000235:genetics*; D015821:Eye Infections, Fungal / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D015725:Fluconazole / Q000494:pharmacology* / Q000627:therapeutic use; D005656:Fungal Proteins / Q000235:genetics / Q000378:metabolism; D006801:Humans; D026901:Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation
D000935:Antifungal Agents; C094693:CDR1 protein, Candida albicans; D005656:Fungal Proteins; D026901:Membrane Transport Proteins; D012333:RNA, Messenger; D015725:Fluconazole